Regulus Therapeutics
San Diego-based Regulus Therapeutics Inc. pioneers first-in-class drugs targeting microRNAs for diverse diseases.
Founded
2007San Diego-based Regulus Therapeutics Inc. pioneers first-in-class drugs targeting microRNAs for diverse diseases.
Regulus Therapeutics Inc., founded in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals, is a clinical-stage biopharmaceutical company based in San Diego, California. The company's core mission is to develop first-in-class drugs that target microRNAs to treat a broad range of diseases, with a particular focus on orphan kidney diseases such as Autosomal Dominant Polycystic Kidney Disease (ADPKD). Regulus leverages its expertise in microRNA-based therapeutics to address high unmet medical needs, aiming to improve the lives of patients and their families.
Notable affiliated individuals include founders from Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus has garnered attention for its innovative approach and has achieved significant milestones, including positive topline data from clinical trials. The company's pioneering work in microRNA therapeutics has positioned it as a leader in the biopharmaceutical industry, making a substantial impact on the treatment landscape for kidney diseases.
Companies similar to Regulus Therapeutics include Regel Therapeutics, Regor Therapeutics, Alnylam Pharmaceuticals aln and Arcturus Therapeutics Holdings.
Regulus Therapeutics was founded in 2007.
Regulus Therapeutics' headquarters is located in San Diego, CA, US.
Regulus Therapeutics' most recent funding round was for $15M (USD) in April 2023.
As of Apr 13, 2023, Regulus Therapeutics has disclosed funding of $380.9M (USD). Undisclosed round amounts are excluded.
Regulus Therapeutics has 30 employees as of Feb 6, 2024.
Arcturus Therapeutics Holdings
arcturusrx.com
